These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 36100873)

  • 1. Investigation of CRS-associated cytokines in CAR-T therapy with meta-GNN and pathway crosstalk.
    Wei Z; Cheng Q; Xu N; Zhao C; Xu J; Kang L; Lou X; Yu L; Feng W
    BMC Bioinformatics; 2022 Sep; 23(1):373. PubMed ID: 36100873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-DHGNN: method for CRS-related cytokines analysis in CAR-T therapy based on meta-learning directed heterogeneous graph neural network.
    Wei Z; Zhao C; Zhang M; Xu J; Xu N; Wu S; Xin X; Yu L; Feng W
    Brief Bioinform; 2024 Mar; 25(3):. PubMed ID: 38546326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular therapy: Immune-related complications.
    Oved JH; Barrett DM; Teachey DT
    Immunol Rev; 2019 Jul; 290(1):114-126. PubMed ID: 31355491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A distinct cytokine network distinguishes chimeric antigen receptor T cell (CAR-T)-associated hemophagocytic lymphohistiocytosis-like toxicity (carHLH) from severe cytokine release syndrome following CAR-T therapy.
    Zu C; Wu S; Zhang M; Wei G; Xu H; Cui J; Chang AH; Huang H; Hu Y
    Cytotherapy; 2023 Nov; 25(11):1167-1175. PubMed ID: 37480884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
    Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K
    Front Immunol; 2021; 12():611366. PubMed ID: 33708205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apoptosis of Hematopoietic Stem Cells Contributes to Bone Marrow Suppression Following Chimeric Antigen Receptor T Cell Therapy.
    Read JA; Rouce RH; Mo F; Mamonkin M; King KY
    Transplant Cell Ther; 2023 Mar; 29(3):165.e1-165.e7. PubMed ID: 36592718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-6/IFN-γ double knockdown CAR-T cells reduce the release of multiple cytokines from PBMCs in vitro.
    Zhang H; Lv X; Kong Q; Tan Y
    Hum Vaccin Immunother; 2022 Dec; 18(1):1-14. PubMed ID: 35049413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Establishment of a cytokine release syndrome associated with chimeric antigen receptor T cell treatment in SCID/Beige mice model].
    Shan JQ; Nan SF; Li F; Shen CY; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1248-1254. PubMed ID: 34915632
    [No Abstract]   [Full Text] [Related]  

  • 9. Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia.
    Hong F; Shi M; Cao J; Wang Y; Gong Y; Gao H; Li Z; Zheng J; Zeng L; He A; Xu K
    J Cell Mol Med; 2021 Dec; 25(24):11063-11074. PubMed ID: 34734474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy.
    Huarte E; O'Connor RS; Peel MT; Nunez-Cruz S; Leferovich J; Juvekar A; Yang YO; Truong L; Huang T; Naim A; Milone MC; Smith PA
    Clin Cancer Res; 2020 Dec; 26(23):6299-6309. PubMed ID: 32998963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
    Brudno JN; Kochenderfer JN
    Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.
    Li J; Wu Z; Zhao N
    Adv Ther; 2019 Oct; 36(10):2881-2894. PubMed ID: 31428935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immunologic aspects of cytokine release syndrome and graft versus host disease following CAR T cell therapy.
    Mansouri V; Yazdanpanah N; Rezaei N
    Int Rev Immunol; 2022; 41(6):649-668. PubMed ID: 34607523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers for Predicting Cytokine Release Syndrome following CD19-Targeted CAR T Cell Therapy.
    Tedesco VE; Mohan C
    J Immunol; 2021 Apr; 206(7):1561-1568. PubMed ID: 33692146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T).
    Alvi RM; Frigault MJ; Fradley MG; Jain MD; Mahmood SS; Awadalla M; Lee DH; Zlotoff DA; Zhang L; Drobni ZD; Hassan MZO; Bassily E; Rhea I; Ismail-Khan R; Mulligan CP; Banerji D; Lazaryan A; Shah BD; Rokicki A; Raje N; Chavez JC; Abramson J; Locke FL; Neilan TG
    J Am Coll Cardiol; 2019 Dec; 74(25):3099-3108. PubMed ID: 31856966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy.
    Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH
    Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators.
    Sachdeva M; Duchateau P; Depil S; Poirot L; Valton J
    J Biol Chem; 2019 Apr; 294(14):5430-5437. PubMed ID: 30804212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel multi-cytokine inhibitor TO-207 specifically inhibits pro-inflammatory cytokine secretion in monocytes without affecting the killing ability of CAR T cells.
    Futami M; Suzuki K; Kato S; Ohmae S; Tahara Y; Nojima M; Imai Y; Mimura T; Watanabe Y; Tojo A
    PLoS One; 2020; 15(4):e0231896. PubMed ID: 32320454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of severe CRS and determination of biomarkers in B cell-acute lymphoblastic leukemia treated with CAR-T cells.
    Wei Z; Xu J; Zhao C; Zhang M; Xu N; Kang L; Lou X; Yu L; Feng W
    Front Immunol; 2023; 14():1273507. PubMed ID: 37854590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies to overcome the side effects of chimeric antigen receptor T cell therapy.
    Mirzaee Godarzee M; Mahmud Hussen B; Razmara E; Hakak-Zargar B; Mohajerani F; Dabiri H; Fatih Rasul M; Ghazimoradi MH; Babashah S; Sadeghizadeh M
    Ann N Y Acad Sci; 2022 Apr; 1510(1):18-35. PubMed ID: 34982476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.